https://www.selleckchem.com/products/ly333531.html
Prospective validation of the above-mentioned potential biomarkers, either alone or in combination, may help to elaborate improved predictive tools. To date, only PD-L1 is clinically validated as a positive predictor of response to immunotherapy, yet the need to refine patient selection has never been stronger, given the indication for checkpoint inhibitors alone or in combination in all non-oncogene driven non-small-cell lung cancer patients receiving front-line therapy. Prospective validation of the above-mentioned potential biomarke
Like
Comment
Share
